Blue Buffalo Pet Products (NASDAQ:BUFF) had its top pick rating reaffirmed by analysts at Citigroup Inc..

Get Blue Buffalo Pet Products Inc alerts:

DowDuPont (NASDAQ:DWDP) had its buy rating reiterated by analysts at Vertical Research. Vertical Research currently has a $79.00 target price on the stock, up from their previous target price of $74.00.

Amicus Therapeutics (NASDAQ:FOLD) had its outperform rating reissued by analysts at Leerink Swann. The firm currently has a $17.00 target price on the stock, down from their previous target price of $18.00.

Nucor Corporation (NYSE:NUE) had its buy rating reiterated by analysts at Jefferies Group LLC.

Steel Dynamics (NASDAQ:STLD) had its buy rating reissued by analysts at Jefferies Group LLC.

Unite Group (NASDAQ:UTGPF) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $8.50 target price on the stock. According to Zacks, “The Unite Group plc is a property investment company. It develops and operates student accommodation primarily in the United Kingdom. The Unite Group plc is headquartered in Bristol, the United Kingdom. “

vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $6.00 target price on the stock. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

Wandisco Plc (NASDAQ:WANSF) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $11.00 target price on the stock. According to Zacks, “WANdisco plc involved in the development and provision of collaboration software. The Company offers active data replication which enables data editing to the cloud and on-premises data centers as well as provides data migration, disaster recovery and hybrid cloud solutions. It also offers cloud services, such as Amazon S3 active migrator, Google cloud active migrator, and Fusion hybrid cloud services as well as provides software maintenance services. WANdisco plc is based in Sheffield, the United Kingdom. “

Weir Group Plc (The) (NASDAQ:WEGRY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “The Weir Group PLC provides engineering solutions. The company’s operating segment consists of Minerals, Oil & Gas and Flow Control. Oil & Gas segment provides products and service solutions to upstream, production, transportation, refining and related industries. Flow Control segment designs and manufactures valves and pumps. Minerals segment offers provision of slurry handling equipment and associated aftermarket support. It also provides specialist support services to the global power generation, industrial and oil and gas sectors. The Weir Group PLC is headquartered in Glasgow, the United Kingdom. “

58.com (NYSE:WUBA) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “58.com Inc. operates online marketplace serving local merchants and consumers in China. It offers housing rental, recruitment, second-hand product, travel, catering, entertainment, and group-buying information. 58.com Inc. is based in Beijing, China. “

Xenetic Biosciences (NASDAQ:XBIO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $3.00 price target on the stock. According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “

Xenia Hotels & Resorts (NYSE:XHR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $23.00 target price on the stock. According to Zacks, “Xenia Hotels & Resorts, Inc. is a self-advised and self-administered REIT. The company invests primarily in premium full service, lifestyle, urban upscale hotels, lodging markets as well as leisure destinations primarily in the United States. Xenia Hotels & Resorts, Inc. is based in Orlando, Florida. “

YRC Worldwide (NASDAQ:YRCW) had its buy rating reiterated by analysts at Aegis. Aegis currently has a $20.00 target price on the stock.